Calumet (CLMT) Q1 2025 earnings summary

Executive summary

• Reported a Q1 2025 net loss of $162.0 million, mainly due to RINs mark-to-market expense, regulatory changes, and debt extinguishment costs, despite improved operational performance and higher Adjusted EBITDA with Tax Attributes of $55.0 million.

• Closed and funded a DOE loan, securing $1.44 billion with $782 million disbursed in Q1, supporting deleveraging, growth, and repayment of prior financings.

• Completed the sale of the Royal Purple industrial business for $110 million, recording a $62.2 million gain and supporting liquidity and debt reduction.

• Announced acceleration of SAF capacity expansion at Montana Renewables to 120–150 million gallons by Q2 2026 for $20–$30 million, with a long-term target of 300 million gallons by 2028.

• Launched a $150 million partial call/redemption of 2026 notes as part of a deleveraging strategy.

Financial highlights

• Q1 2025 Adjusted EBITDA with Tax Attributes rose to $55.0 million from $28.1 million in Q1 2024, with segment improvements in Specialty Products ($56.3 million), Performance Brands ($15.8 million), and Montana Renewables ($3.3 million).

• Sales were $993.9 million, down 1.2% year-over-year, with declines in Specialty offset by growth in Montana/Renewables and Performance Brands.

• Achieved a $22 million year-over-year reduction in operating costs, with Montana Renewables operating costs at $0.49/gal.

• Ended Q1 with consolidated liquidity of $542.7 million, including $123.4 million in cash and $339.3 million in available credit; restricted group liquidity at $347.3 million.

• Operating cash flow was negative $110.6 million, impacted by debt extinguishment and working capital changes.

Outlook and guidance

• Montana Renewables targets 120–150 million gallons of SAF capacity by Q2 2026 for $20–$30 million, with a long-term goal of 300 million gallons by 2028.

• Management expects continued strong demand and healthy margins for specialty and renewable products into Q2 2025, with ongoing cost reduction initiatives.

• Capital expenditures for 2025 are forecasted at $60–90 million, excluding MaxSAF project spending.

• RVO update anticipated; potential for increased biodiesel production if mandates rise.